Skip to main content
Erschienen in: Breast Cancer Research 3/2009

01.06.2009 | Review

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

verfasst von: Joan S Lewis-Wambi, V Craig Jordan

Erschienen in: Breast Cancer Research | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The link between estrogen and the development and proliferation of breast cancer is well documented. Estrogen stimulates growth and inhibits apoptosis through estrogen receptor-mediated mechanisms in many cell types. Interestingly, there is strong evidence that estrogen induces apoptosis in breast cancer and other cell types. Forty years ago, before the development of tamoxifen, high-dose estrogen was used to induce tumor regression of hormone-dependent breast cancer in post-menopausal women. While the mechanisms by which estrogen induces apoptosis were not completely known, recent evidence from our laboratory and others demonstrates the involvement of the extrinsic (Fas/FasL) and the intrinsic (mitochondria) pathways in this process. We discuss the different apoptotic signaling pathways involved in E2 (17β-estradiol)-induced apoptosis, including the intrinsic and extrinsic apoptosis pathways, the NF-κB (nuclear factor-kappa-B)-mediated survival pathway as well as the PI3K (phosphoinositide 3-kinase)/Akt signaling pathway. Breast cancer cells can also be sensitized to estrogen-induced apoptosis through suppression of glutathione by BSO (L-buthionine sulfoximine). This finding has implications for the control of breast cancer with low-dose estrogen and other targeted therapeutic drugs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Russo IH, Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998, 3: 49-61. 10.1023/A:1018770218022.CrossRefPubMed Russo IH, Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998, 3: 49-61. 10.1023/A:1018770218022.CrossRefPubMed
2.
Zurück zum Zitat Beatson CT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 2: 101-111. Beatson CT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 2: 101-111.
3.
Zurück zum Zitat Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.CrossRefPubMed Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.CrossRefPubMed
4.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
5.
Zurück zum Zitat Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.
6.
Zurück zum Zitat Iwase H: Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 2008, 15: 278-290. 10.1007/s12282-008-0071-y.CrossRefPubMed Iwase H: Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 2008, 15: 278-290. 10.1007/s12282-008-0071-y.CrossRefPubMed
7.
Zurück zum Zitat Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996, 12: 2315-2324.PubMed Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996, 12: 2315-2324.PubMed
8.
Zurück zum Zitat Foster JS, Wimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol. 1996, 10: 488-498. 10.1210/me.10.5.488.PubMed Foster JS, Wimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol. 1996, 10: 488-498. 10.1210/me.10.5.488.PubMed
9.
Zurück zum Zitat Pietras RJ, Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007, 13: 4672-4676. 10.1158/1078-0432.CCR-07-1373.CrossRefPubMed Pietras RJ, Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007, 13: 4672-4676. 10.1158/1078-0432.CCR-07-1373.CrossRefPubMed
10.
Zurück zum Zitat Moriarty K, Kim KH, Bender JR: Minireview: estrogen receptor-mediated rapid signaling. Endocrinology. 2006, 147: 5557-5563. 10.1210/en.2006-0729.CrossRefPubMed Moriarty K, Kim KH, Bender JR: Minireview: estrogen receptor-mediated rapid signaling. Endocrinology. 2006, 147: 5557-5563. 10.1210/en.2006-0729.CrossRefPubMed
11.
Zurück zum Zitat Pedram A, Razandi M, Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006, 20: 1996-2009. 10.1210/me.2005-0525.CrossRefPubMed Pedram A, Razandi M, Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006, 20: 1996-2009. 10.1210/me.2005-0525.CrossRefPubMed
12.
Zurück zum Zitat Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A: Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol. 2003, 17: 818-830. 10.1210/me.2002-0330.CrossRefPubMed Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A: Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol. 2003, 17: 818-830. 10.1210/me.2002-0330.CrossRefPubMed
13.
Zurück zum Zitat Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233. 10.1210/er.2006-0045.CrossRefPubMedPubMedCentral Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233. 10.1210/er.2006-0045.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 2000, 65: 593-598. 10.1016/S0039-128X(00)00172-0.CrossRefPubMed Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 2000, 65: 593-598. 10.1016/S0039-128X(00)00172-0.CrossRefPubMed
15.
Zurück zum Zitat Jordan VC: The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer – survival or death?. J Clin Oncol. 2008, 26: 3073-3082. 10.1200/JCO.2008.17.5190.CrossRefPubMed Jordan VC: The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer – survival or death?. J Clin Oncol. 2008, 26: 3073-3082. 10.1200/JCO.2008.17.5190.CrossRefPubMed
16.
Zurück zum Zitat Jordan VC, Lewis JS, Osipo C, Cheng D: The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast. 2005, 14: 624-630. 10.1016/j.breast.2005.08.022.CrossRefPubMed Jordan VC, Lewis JS, Osipo C, Cheng D: The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast. 2005, 14: 624-630. 10.1016/j.breast.2005.08.022.CrossRefPubMed
17.
Zurück zum Zitat Lewis JS, Cheng D, Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer. 2004, 90: 944-949. 10.1038/sj.bjc.6601627.CrossRefPubMedPubMedCentral Lewis JS, Cheng D, Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer. 2004, 90: 944-949. 10.1038/sj.bjc.6601627.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005, 97: 1746-1759.CrossRefPubMed Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005, 97: 1746-1759.CrossRefPubMed
19.
Zurück zum Zitat Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol. 2001, 79: 115-125. 10.1016/S0960-0760(01)00151-0.CrossRefPubMed Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol. 2001, 79: 115-125. 10.1016/S0960-0760(01)00151-0.CrossRefPubMed
20.
Zurück zum Zitat Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001, 93: 1714-1723. 10.1093/jnci/93.22.1714.CrossRefPubMed Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001, 93: 1714-1723. 10.1093/jnci/93.22.1714.CrossRefPubMed
21.
Zurück zum Zitat Swaby RF, Jordan VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008, 8: 124-133. 10.3816/CBC.2008.n.012.CrossRefPubMed Swaby RF, Jordan VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008, 8: 124-133. 10.3816/CBC.2008.n.012.CrossRefPubMed
22.
Zurück zum Zitat Wolf DM, Jordan VC: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993, 127: 23-33.CrossRefPubMed Wolf DM, Jordan VC: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993, 127: 23-33.CrossRefPubMed
23.
Zurück zum Zitat Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000, 6: 2028-2036.PubMed Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000, 6: 2028-2036.PubMed
24.
Zurück zum Zitat Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, Fine RL: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996, 88: 908-917. 10.1093/jnci/88.13.908.CrossRefPubMed Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, Fine RL: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996, 88: 908-917. 10.1093/jnci/88.13.908.CrossRefPubMed
25.
Zurück zum Zitat Nilsen J, Mor G, Naftolin F: Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol. 2000, 43: 64-78. 10.1002/(SICI)1097-4695(200004)43:1<64::AID-NEU6>3.0.CO;2-7.CrossRefPubMed Nilsen J, Mor G, Naftolin F: Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol. 2000, 43: 64-78. 10.1002/(SICI)1097-4695(200004)43:1<64::AID-NEU6>3.0.CO;2-7.CrossRefPubMed
26.
Zurück zum Zitat Saintier D, Khanine V, Uzan B, Ea HK, de Vernejoul MC, Cohen-Solal ME: Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol. 2006, 99: 165-173. 10.1016/j.jsbmb.2006.01.009.CrossRefPubMed Saintier D, Khanine V, Uzan B, Ea HK, de Vernejoul MC, Cohen-Solal ME: Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol. 2006, 99: 165-173. 10.1016/j.jsbmb.2006.01.009.CrossRefPubMed
27.
Zurück zum Zitat Okasha SA, Ryu S, Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS: Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology. 2001, 163: 49-62. 10.1016/S0300-483X(01)00374-2.CrossRefPubMed Okasha SA, Ryu S, Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS: Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology. 2001, 163: 49-62. 10.1016/S0300-483X(01)00374-2.CrossRefPubMed
28.
Zurück zum Zitat Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst. 1992, 84: 580-591. 10.1093/jnci/84.8.580.CrossRefPubMed Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst. 1992, 84: 580-591. 10.1093/jnci/84.8.580.CrossRefPubMed
29.
Zurück zum Zitat Levenson AS, Jordan VC: Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol. 1994, 51: 229-239. 10.1016/0960-0760(94)90035-3.CrossRefPubMed Levenson AS, Jordan VC: Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol. 1994, 51: 229-239. 10.1016/0960-0760(94)90035-3.CrossRefPubMed
30.
Zurück zum Zitat Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981, 304: 16-21.CrossRefPubMed Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981, 304: 16-21.CrossRefPubMed
31.
Zurück zum Zitat Lewis JS, Osipo C, Meeke K, Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol. 2005, 94: 131-141. 10.1016/j.jsbmb.2004.12.032.CrossRefPubMed Lewis JS, Osipo C, Meeke K, Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol. 2005, 94: 131-141. 10.1016/j.jsbmb.2004.12.032.CrossRefPubMed
32.
Zurück zum Zitat Song RX, Zhang Z, Mor G, Santen RJ: Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis. 2005, 10: 667-678. 10.1007/s10495-005-1903-2.CrossRefPubMed Song RX, Zhang Z, Mor G, Santen RJ: Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis. 2005, 10: 667-678. 10.1007/s10495-005-1903-2.CrossRefPubMed
33.
Zurück zum Zitat Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H: Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol. 2008, 630: 19-34.CrossRefPubMedPubMedCentral Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H: Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol. 2008, 630: 19-34.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC: Buthionine sulfoximine sensitizes anti-hormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res. 2008, 10: R104-10.1186/bcr2208.CrossRefPubMedPubMedCentral Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC: Buthionine sulfoximine sensitizes anti-hormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res. 2008, 10: R104-10.1186/bcr2208.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Osipo C, Gajdos C, Liu H, Chen B, Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003, 95: 1597-1608.CrossRefPubMed Osipo C, Gajdos C, Liu H, Chen B, Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003, 95: 1597-1608.CrossRefPubMed
36.
Zurück zum Zitat Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA: Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res. 2009, 7: 498-510. 10.1158/1541-7786.MCR-08-0415.CrossRefPubMedPubMedCentral Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA: Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res. 2009, 7: 498-510. 10.1158/1541-7786.MCR-08-0415.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Haddow A, Watkinson JM, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ. 1944, 2: 393-398. 10.1136/bmj.2.4368.393.CrossRefPubMedPubMedCentral Haddow A, Watkinson JM, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ. 1944, 2: 393-398. 10.1136/bmj.2.4368.393.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA. 1977, 237: 2079-2078. 10.1001/jama.237.19.2079.CrossRefPubMed Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA. 1977, 237: 2079-2078. 10.1001/jama.237.19.2079.CrossRefPubMed
39.
Zurück zum Zitat Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971, 25: 270-275.CrossRefPubMedPubMedCentral Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971, 25: 270-275.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A: High-dose estrogen treatment in post-menopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001, 67: 111-116. 10.1023/A:1010619225209.CrossRefPubMed Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A: High-dose estrogen treatment in post-menopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001, 67: 111-116. 10.1023/A:1010619225209.CrossRefPubMed
41.
Zurück zum Zitat Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat. 1999, 54: 117-122. 10.1023/A:1006185805079.CrossRefPubMed Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat. 1999, 54: 117-122. 10.1023/A:1006185805079.CrossRefPubMed
42.
Zurück zum Zitat Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Fleming G, Silverman P, Dickler M, L Carey, Marcom PK: A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer [abstract]. Cancer Res. 2009, 69: s67- Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Fleming G, Silverman P, Dickler M, L Carey, Marcom PK: A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer [abstract]. Cancer Res. 2009, 69: s67-
43.
Zurück zum Zitat Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene. 2003, 22: 8543-8567. 10.1038/sj.onc.1207107.CrossRefPubMed Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene. 2003, 22: 8543-8567. 10.1038/sj.onc.1207107.CrossRefPubMed
44.
Zurück zum Zitat Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
45.
Zurück zum Zitat Ziegler DS, Kung AL: Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol. 2008, 20: 97-103. 10.1097/CCO.0b013e3282f310f6.CrossRefPubMed Ziegler DS, Kung AL: Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol. 2008, 20: 97-103. 10.1097/CCO.0b013e3282f310f6.CrossRefPubMed
46.
Zurück zum Zitat Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10: 26-35. 10.1038/sj.cdd.4401186.CrossRefPubMed Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10: 26-35. 10.1038/sj.cdd.4401186.CrossRefPubMed
47.
Zurück zum Zitat Tsujimoto Y: Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep. 2002, 22: 47-58. 10.1023/A:1016061006256.CrossRefPubMed Tsujimoto Y: Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep. 2002, 22: 47-58. 10.1023/A:1016061006256.CrossRefPubMed
48.
Zurück zum Zitat Talapatra S, Thompson CB: Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther. 2001, 298: 873-878.PubMed Talapatra S, Thompson CB: Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther. 2001, 298: 873-878.PubMed
49.
Zurück zum Zitat Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC: Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003, 95: 1586-1597.CrossRefPubMed Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC: Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003, 95: 1586-1597.CrossRefPubMed
50.
Zurück zum Zitat Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res. 2001, 7: 3156-3165.PubMed Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res. 2001, 7: 3156-3165.PubMed
51.
Zurück zum Zitat Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC: Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer. 2000, 83: 782-791. 10.1054/bjoc.2000.1326.CrossRefPubMedPubMedCentral Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC: Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer. 2000, 83: 782-791. 10.1054/bjoc.2000.1326.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F: Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol. 2000, 73: 185-194. 10.1016/S0960-0760(00)00081-9.CrossRefPubMed Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F: Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol. 2000, 73: 185-194. 10.1016/S0960-0760(00)00081-9.CrossRefPubMed
53.
Zurück zum Zitat Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998, 1: 543-551. 10.1016/S1097-2765(00)80054-4.CrossRefPubMed Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998, 1: 543-551. 10.1016/S1097-2765(00)80054-4.CrossRefPubMed
54.
Zurück zum Zitat Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM: Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem. 2001, 276: 4964-4971. 10.1074/jbc.M009251200.CrossRefPubMed Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM: Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem. 2001, 276: 4964-4971. 10.1074/jbc.M009251200.CrossRefPubMed
55.
Zurück zum Zitat Krishnan V, Wang X, Safe S: Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem. 1994, 269: 15912-15917.PubMed Krishnan V, Wang X, Safe S: Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem. 1994, 269: 15912-15917.PubMed
56.
Zurück zum Zitat Porter W, Saville B, Hoivik D, Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol. 1997, 11: 1569-1580. 10.1210/me.11.11.1569.CrossRefPubMed Porter W, Saville B, Hoivik D, Safe S: Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol. 1997, 11: 1569-1580. 10.1210/me.11.11.1569.CrossRefPubMed
57.
Zurück zum Zitat Duan R, Porter W, Safe S: Estrogen-induced c-fos protoonco-gene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology. 1998, 139: 1981-1990. 10.1210/en.139.4.1981.PubMed Duan R, Porter W, Safe S: Estrogen-induced c-fos protoonco-gene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology. 1998, 139: 1981-1990. 10.1210/en.139.4.1981.PubMed
58.
Zurück zum Zitat Sun G, Porter W, Safe S: Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol. 1998, 12: 882-890. 10.1210/me.12.6.882.PubMed Sun G, Porter W, Safe S: Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol. 1998, 12: 882-890. 10.1210/me.12.6.882.PubMed
59.
Zurück zum Zitat Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S: Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem. 2000, 275: 5379-5387. 10.1074/jbc.275.8.5379.CrossRefPubMed Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S: Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem. 2000, 275: 5379-5387. 10.1074/jbc.275.8.5379.CrossRefPubMed
60.
Zurück zum Zitat Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009, 15: 1126-1132. 10.1158/1078-0432.CCR-08-0144.CrossRefPubMedPubMedCentral Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009, 15: 1126-1132. 10.1158/1078-0432.CCR-08-0144.CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007, 25: 1114-1120. 10.1200/JCO.2006.07.1191.CrossRefPubMed O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007, 25: 1114-1120. 10.1200/JCO.2006.07.1191.CrossRefPubMed
62.
Zurück zum Zitat Bellacosa A, Testa JR, Staal SP, Tsichlis PN: A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991, 254: 274-277. 10.1126/science.1833819.CrossRefPubMed Bellacosa A, Testa JR, Staal SP, Tsichlis PN: A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991, 254: 274-277. 10.1126/science.1833819.CrossRefPubMed
63.
Zurück zum Zitat Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.CrossRefPubMed Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.CrossRefPubMed
64.
Zurück zum Zitat del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997, 278: 687-689. 10.1126/science.278.5338.687.CrossRefPubMed del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997, 278: 687-689. 10.1126/science.278.5338.687.CrossRefPubMed
65.
Zurück zum Zitat John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, Thomas TJ: Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008, 68: 7855-7863. 10.1158/0008-5472.CAN-07-5875.CrossRefPubMed John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, Thomas TJ: Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008, 68: 7855-7863. 10.1158/0008-5472.CAN-07-5875.CrossRefPubMed
66.
Zurück zum Zitat Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008, 27: 5511-5526. 10.1038/onc.2008.246.CrossRefPubMed Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008, 27: 5511-5526. 10.1038/onc.2008.246.CrossRefPubMed
67.
Zurück zum Zitat Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998, 16: 225-260. 10.1146/annurev.immunol.16.1.225.CrossRefPubMed Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998, 16: 225-260. 10.1146/annurev.immunol.16.1.225.CrossRefPubMed
68.
Zurück zum Zitat Dutta J, Fan Y, Gupta N, Fan G, Gelinas C: Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006, 25: 6800-6816. 10.1038/sj.onc.1209938.CrossRefPubMed Dutta J, Fan Y, Gupta N, Fan G, Gelinas C: Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006, 25: 6800-6816. 10.1038/sj.onc.1209938.CrossRefPubMed
69.
Zurück zum Zitat Stoffel A, Levine AJ: Activation of NF-kappaB by the API2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis: a directional link between NF-kappaB and p53. Cell Cycle. 2004, 3: 1017-1020.CrossRefPubMed Stoffel A, Levine AJ: Activation of NF-kappaB by the API2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis: a directional link between NF-kappaB and p53. Cell Cycle. 2004, 3: 1017-1020.CrossRefPubMed
70.
Zurück zum Zitat Krasil'nikov MA, Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA: NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem. 2009, 324: 65-71. 10.1007/s11010-008-9985-0.CrossRefPubMed Krasil'nikov MA, Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA: NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem. 2009, 324: 65-71. 10.1007/s11010-008-9985-0.CrossRefPubMed
71.
Zurück zum Zitat Voehringer DW: BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med. 1999, 27: 945-950. 10.1016/S0891-5849(99)00174-4.CrossRefPubMed Voehringer DW: BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med. 1999, 27: 945-950. 10.1016/S0891-5849(99)00174-4.CrossRefPubMed
72.
Zurück zum Zitat Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE: Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem. 1996, 67: 1259-1267.CrossRefPubMed Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE: Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem. 1996, 67: 1259-1267.CrossRefPubMed
73.
Zurück zum Zitat Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP: Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res. 1999, 246: 183-192. 10.1006/excr.1998.4303.CrossRefPubMed Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP: Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res. 1999, 246: 183-192. 10.1006/excr.1998.4303.CrossRefPubMed
74.
Zurück zum Zitat Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF: Glutathione and drug resistance. Cancer Invest. 1996, 14: 158-168. 10.3109/07357909609018891.CrossRefPubMed Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF: Glutathione and drug resistance. Cancer Invest. 1996, 14: 158-168. 10.3109/07357909609018891.CrossRefPubMed
75.
Zurück zum Zitat Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000, 89: 1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0.CrossRefPubMed Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000, 89: 1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0.CrossRefPubMed
76.
Zurück zum Zitat Bailey HH: L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact. 1998, 111–112: 239-254. 10.1016/S0009-2797(97)00164-6.CrossRefPubMed Bailey HH: L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact. 1998, 111–112: 239-254. 10.1016/S0009-2797(97)00164-6.CrossRefPubMed
77.
Zurück zum Zitat Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol. 1994, 12: 194-205.PubMed Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol. 1994, 12: 194-205.PubMed
78.
Zurück zum Zitat Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G: Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997, 89: 1789-1796. 10.1093/jnci/89.23.1789.CrossRefPubMed Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G: Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997, 89: 1789-1796. 10.1093/jnci/89.23.1789.CrossRefPubMed
79.
Zurück zum Zitat Vasilevskaya I, O'Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat. 2003, 6: 147-156. 10.1016/S1368-7646(03)00043-8.CrossRefPubMed Vasilevskaya I, O'Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat. 2003, 6: 147-156. 10.1016/S1368-7646(03)00043-8.CrossRefPubMed
80.
Zurück zum Zitat Altiok N, Koyuturk M, Altiok S: JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. Breast Cancer Res Treat. 2007, 105: 247-254. 10.1007/s10549-006-9451-1.CrossRefPubMed Altiok N, Koyuturk M, Altiok S: JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. Breast Cancer Res Treat. 2007, 105: 247-254. 10.1007/s10549-006-9451-1.CrossRefPubMed
81.
Zurück zum Zitat Park J, Kim I, Oh YJ, Lee K, Han PL, Choi EJ: Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2. J Biol Chem. 1997, 272: 16725-16728. 10.1074/jbc.272.27.16725.CrossRefPubMed Park J, Kim I, Oh YJ, Lee K, Han PL, Choi EJ: Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2. J Biol Chem. 1997, 272: 16725-16728. 10.1074/jbc.272.27.16725.CrossRefPubMed
82.
Zurück zum Zitat Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002, 23: 279-302. 10.1210/er.23.3.279.CrossRefPubMed Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002, 23: 279-302. 10.1210/er.23.3.279.CrossRefPubMed
84.
Zurück zum Zitat Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation Investigators: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002, 87: 3609-3617. 10.1210/jc.87.8.3609.CrossRefPubMed Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation Investigators: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002, 87: 3609-3617. 10.1210/jc.87.8.3609.CrossRefPubMed
85.
Zurück zum Zitat Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R: Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001, 276: 8836-8840. 10.1074/jbc.M010764200.CrossRefPubMed Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R: Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001, 276: 8836-8840. 10.1074/jbc.M010764200.CrossRefPubMed
86.
Zurück zum Zitat Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007, 130: 811-823. 10.1016/j.cell.2007.07.025.CrossRefPubMed Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007, 130: 811-823. 10.1016/j.cell.2007.07.025.CrossRefPubMed
87.
Zurück zum Zitat Zeitlin BD, Zeitlin IJ, Nor JE: Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol. 2008, 26: 4180-4188. 10.1200/JCO.2007.15.7693.CrossRefPubMedPubMedCentral Zeitlin BD, Zeitlin IJ, Nor JE: Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol. 2008, 26: 4180-4188. 10.1200/JCO.2007.15.7693.CrossRefPubMedPubMedCentral
88.
Zurück zum Zitat Stein CA, Benimetskaya L, Mani S: Antisense strategies for oncogene inactivation. Semin Oncol. 2005, 32: 563-572. 10.1053/j.seminoncol.2005.09.003.CrossRefPubMed Stein CA, Benimetskaya L, Mani S: Antisense strategies for oncogene inactivation. Semin Oncol. 2005, 32: 563-572. 10.1053/j.seminoncol.2005.09.003.CrossRefPubMed
89.
Zurück zum Zitat Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63: 8118-8121.PubMed Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63: 8118-8121.PubMed
Metadaten
Titel
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
verfasst von
Joan S Lewis-Wambi
V Craig Jordan
Publikationsdatum
01.06.2009
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 3/2009
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2255

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research 3/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.